SLC5A2 and chronic kidney disease: Major cardiovascular outcome trials in type 2 diabetes, including EMPA‐REG OUTCOME, CANVAS, and DECLARE‐TIMI 58, have demonstrated significant renal benefits with SGLT‐2 inhibitors therapy, such as slower CKD progression and fewer cardiovascular events compared to placebo [15, 21, 22].